An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection in Human Immunodeficiency Virus (HIV) Subjects Diagnosed With Kaposi Sarcoma (KS)
Phase of Trial: Phase I
Latest Information Update: 27 Nov 2018
At a glance
- Drugs Tc 99m tilmanocept (Primary)
- Indications Kaposi's sarcoma
- Focus Adverse reactions
- Sponsors Navidea Biopharmaceuticals
- 27 Nov 2018 According to a Navidea Biopharmaceuticals media release, data from the study will be presented at the RSNA 104thScientific Assembly and Annual Meeting 2018.
- 14 Aug 2018 Planned End Date changed from 31 Oct 2018 to 1 Mar 2019.
- 14 Aug 2018 Planned primary completion date changed from 31 Aug 2018 to 1 Dec 2018.